PM360 2018 Trailblazer Awards Silver Specialty Pharma/Biotech Company of the Year Salix Pharmaceuticals

Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For almost 30 years, Salix has licensed, developed, and marketed innovative products to improve patients’ lives and arm healthcare providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. healthcare providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists, and primary care. Salix is headquartered in Bridgewater, New Jersey.

Salix Pharmaceuticals’ headquarters in Bridgewater, New Jersey.

Innovation and Talent Development

  • We employ dedicated and innovative team members who are driven to solve problems. We improve upon existing treatments, uncover new breakthroughs, and deliver comprehensive practice support to help HCPs provide best-in-class care. The landscape of healthcare will continue to change and new patients will continue to present with new needs. That’s why there is no finish line for our innovation and no limits to our potential.

Social Responsibility

  • At Salix, we are committed to moving gastrointestinal treatment forward in a way that’s guided by the utmost integrity. We are committed to upholding high ethical standards in all aspects of our business and treating our team members, shareholders, and peers with mutual respect. Above all, we believe that we have a responsibility to do the right thing for the patients who benefit from our products.

Ads

You May Also Like

PM360 2019 Trailblazer Awards Sponsors

Imagination Award Sponsor   Premier Brand Champion & Roundtable Sponsor   Platinum Sponsors   ...

ELITE 2018 Mentor Jim Pellettiere of Amgen

Jim Pellettiere Marketing Director Amgen The Modern Mentor “Jim Pellettiere is a Modern Mentor,” ...

Defining Patient Experience Nuances

It is an understatement at this point—and hopefully glaringly obvious to everybody reading this—to ...